CN105950477A - Medium, biotransformation mycelium, extract product and application - Google Patents
Medium, biotransformation mycelium, extract product and application Download PDFInfo
- Publication number
- CN105950477A CN105950477A CN201610261325.4A CN201610261325A CN105950477A CN 105950477 A CN105950477 A CN 105950477A CN 201610261325 A CN201610261325 A CN 201610261325A CN 105950477 A CN105950477 A CN 105950477A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- mycelium
- water
- radix puerariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 43
- 230000036983 biotransformation Effects 0.000 title abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 21
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 229930006000 Sucrose Natural products 0.000 claims abstract description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 10
- 235000013312 flour Nutrition 0.000 claims abstract description 8
- 235000013402 health food Nutrition 0.000 claims abstract description 6
- 244000309464 bull Species 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000289669 Erinaceus europaeus Species 0.000 claims description 4
- 241000577951 Hydnum Species 0.000 claims description 4
- 230000002443 hepatoprotective effect Effects 0.000 claims description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 18
- 238000001035 drying Methods 0.000 abstract description 4
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 238000001291 vacuum drying Methods 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 235000015099 wheat brans Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- 229960004756 ethanol Drugs 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 231100000753 hepatic injury Toxicity 0.000 description 9
- 229940118019 malondialdehyde Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000003304 gavage Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- -1 therefore in liver Chemical compound 0.000 description 5
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 4
- 241000219780 Pueraria Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 108010059892 Cellulase Proteins 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 229940106157 cellulase Drugs 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000019160 vitamin B3 Nutrition 0.000 description 3
- 239000011708 vitamin B3 Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000913776 Pueraria montana Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241001327284 Sorghastrum nutans Species 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940110436 fortesta Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229940054192 micro-guard Drugs 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Alternative & Traditional Medicine (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of biological pharmacy, and specifically relates to a medium, biotransformation mycelium, extract product and application. The medium comprises the following components: by weight, 490-350 parts of wheat bran, 140-100 parts of corn flour, 63-45 parts of bran coat, 7-5 parts of white sugar, 300-500 parts of radix puerariae, and 400-600 parts of water. The preparation method of the biotransformation mycelium includes inoculating the hericium erinaceus fungus strain into the medium, cultivating the hericium erinaceus for 30-40 days at 20-27 DEG C, and drying the product to obtain the biotransformation mycelium. The preparation method of the extract product includes performing water extraction of the biotransformation mycelium to obtain the extract, and performing vacuum concentration and vacuum drying of the extract to obtain the extract product. The extract product has outstanding antialcoholism effect, so that the extract product can be used for preparing the medicament protecting liver or the health food preventing alcoholism.
Description
Technical field
The invention belongs to biological pharmacy technical field, be specifically related to a kind of culture medium, bioconversion mycelium, extract and purposes.
Background technology
One sample survey results of China shows, China's Patients with Fatty Liver about people more than 100,000,000, and the trouble of alcoholic fatty liver
Sick rate up to 23.34%.Long-term alcohol may result in hepatocyte and happens over and over again degeneration, necrosis and regeneration, ultimately results in liver fiber
Change and liver cirrhosis.Research shows, the ultimate principle of alcoholic fatty liver morbidity is that acetaldehyde is to hepatocellular toxic action.Patient's length
Phase drinks, and can have a slight discomfort, general lassitude, fatiguability, inappetence, abdominal part distension, Nausea and vomiting, upper left abdomen and
Pain etc. under umbilicus week or xiphoid-process；Small number of patients has low grade fever, suffers from diarrhoea and urinates the symptoms such as color depth；The also appearance obesity phenomenon having.Simultaneously by
In living environment the best (such as: air pollution), toxin is easily accessible internal person, working environment the best (such as: be engaged in harmful work) person,
Treating with courtesy various, frequent alcohol user, frequent smoker, involuntary smoker, frequent drug administration person etc. easily has chemical liver injury
Dangerous.In the urgent need to a kind of, chemical liver injury there are the therapeutical effect medicine that toxic and side effects is the least simultaneously or health food, but,
The most inreal there is such a product.
Liver is the major organs of alcohol metabolism, and after drinking, ethanol is quickly absorbed at gastrointestinal, and the ethanol of 90% is made through liver
With becoming acetaldehyde.The major toxicity of liver is act as by acetaldehyde: (1) reduces the liver oxidation to fatty acid；(2) liver is affected micro-
Guard system, makes particulate protein secretion reduce, causes lipid and protein to deposit in hepatocyte；(3) during liver metabolism,
Due to oxidation, reduction dysequilibrium, ethanol can make phosphoglycerol concentration raise, and suppresses tricarboxylic acid cycle, makes fatty acid oxidation divide
Solving and reduce, fatty acid and phosphoglycerol are the raw materials of synthesis TG, therefore in liver, TG synthesis increases.
Hericium erinaceus (Bull. Ex Fr.) Pers., nature and flavor are sweet flat, enter spleen, stomach, kidney three warp, and function strengthens the spleen and stomach, Invigorate the kidney and fill the marrow." Xinhua's book on Chinese herbal medicine outline " is remembered
Carry: functions such as " property put down for herb, sweet in the mouth, and favourable the five internal organs, aid digestion, nourishing the liver hold up liver, anticancer ".Outside containing polysaccharide, polypeptide,
Possibly together with multivitamin, 18 kinds of aminoacid, protein content reaches more than 20%, and what these materials were consumed after drinking just
Element.Wherein rich in vitamin PP (niacin amide), niacin amide is synthesis oxidized form nicotinamide adenine dinucleotide
(NAD+) raw material, niacin amide (vitamin PP) is the most, and NAD+ is the most, and the activity of ethanol dehydrogenase is the strongest, metabolism
Become acetaldehyde the fastest；In like manner, the coenzyme of aldehyde dehydrogenase is also oxidized form nicotinamide adenine dinucleotide (NAD+), Buddhist nun
Gram amide (vitamin PP) is the most, and the NAD+ of internal synthesis is the most, and the activity of aldehyde dehydrogenase is the strongest, is metabolized to nontoxic
Acetic acid the fastest, thus relieve acetaldehyde and the ethanol toxic action to body.Accelerating alcohol and the metabolism of acetaldehyde, metabolism
Becoming avirulence acetic acid, reaching relieves the effect of alcohol holds up the purpose of liver.In Hericium erinaceus (Bull. Ex Fr.) Pers., Vitamin C content is up to 26mg/100g, and vitamin C has
There is antioxidation, remove the function of free radical.Ethanol and acetaldehyde all can produce free radical in metabolic process, and radical pair body
Greatly damage can be caused.Vitamin C removes free radical, and protection body is from the damage of free radical, and reaching relieves the effect of alcohol holds up the purpose of liver.
Radix Puerariae, property is sweet, pungent, cool, returns lung, spleen, stomach warp, effect energy relieving muscles diaphoresis, rash, promoting the production of body fluid to quench thirst relieving restlessness, yang invigorating
Antidiarrheal, treatment skin ulcer of invigorating blood circulation, relieve the effect of alcohol.Radix Puerariae is used for " alcoholic intoxication " in the Tang Dynasty, as Thousand Golden Prescriptions smashes juice to controlling with fresh Radix Puerariae
The liquor-saturated person that do not wakes up.Song dynasty amplification on Canon of Materia Medica takes powder with Radix Puerariae and controls drunken person, says: " sick wine and thirsty person, row the best ".Drink
The excessively many excessive thirst of person, impairing the spleen and stomach person may occur in which again the disease such as poor appetite, vomiting.Radix Puerariae energy " main vomiting " (" legendary god of farming's wood grass warp "),
" whetting the appetite ... only excessive thirst " (" property of medicine opinion "), therefore to drunk person, have effect to the ill.Radix Puerariae extracting solution can substantially reduce by four
Mice SGPT caused by chlorination carbon and ethanol raises, the generation of suppression hepatocyte malondialdehyde (MDA), improves
Liver glycogen caused by Carbon tetrachloride reduces, and alleviates pathology of livers, and prompting Radix Puerariae has protective action to hepatic injury.Research is had to send out
The central nervous system of mice excitement that low dosage ethylism is caused by existing Radix Puerariae extracting solution has obvious inhibitory action, and to high agent
Measure rat and central nervous system of mice suppression that ethylism causes, then have certain antagonism, illustrate that Radix Puerariae has alcoholic intoxication
Effect with relieving alcoholic intoxication.
Bioconversion " mycelium " refers to utilize the metabolic function of mycelium (including fungus), makes the bioid that Organic substance decomposes
Learn course of reaction.With suitable culture medium as nutrition, produce abundant secondary generation by mycelial growth metabolism and vital movement
Thank to product.Use for reference Chinese medicine prescription thought, using single medicinal material, there is similar or synergistic Chinese medicine enter as partial medium
Row mycelium convert, the bioactive ingredients that different strains mutation " secondary " metabolism is different, then carry out " post-directed training, two-way
Convert " bio-conversion process, different biological active matter raw material can be obtained, it is therefore an objective to produce new, strengthen effect or reduction
Single medicine ill effect.
In order to strengthen the dispelling effects of alcohol of Radix Puerariae, Radix Puerariae and Hericium erinaceus (Bull. Ex Fr.) Pers. are usually mixed by the technical scheme used at present, and tie
Close other materials and make compositions, such as China Patent Publication No. CN 102451225A, CN 101683157A and CN 1736261A.
As China Patent Publication No. CN 1736261A discloses a kind of alcohol-dissolving liver-protecting healthy food, it is made up of following components and weight ratio:
Hericium erinaceus (Bull. Ex Fr.) Pers. 35-45 part, Radix Puerariae 25-35 part, Concha Ostreae 16-24 part, Radix Glycyrrhizae 8-12 part, Radix Paeoniae Alba 8-12 part, Rhizoma Cyperi 8-12 part.
Its dispelling effects of alcohol need to strengthen.
Summary of the invention
It is contemplated that overcome the deficiencies in the prior art, interdisciplinary innovation, multidisciplinary in conjunction with microbiology, Chinese materia medica etc., it is provided that
A kind of culture medium, bioconversion mycelium, extract and purposes, described preparation method is simple, and cost is relatively low, described extract
There is dispelling effects of alcohol, be used for preparing hepatoprotective medicine or Dealcoholic sobering-up health food.
Culture medium of the present invention includes the component of following weight portion:
Testa Tritici 490～350 parts, Semen Maydis flour 140～100 parts, bran coat 63～45 parts, white sugar 7～5 parts, Radix Puerariae 300～500
Part, water 400～600 parts.
Preferably, described culture medium includes the component of following weight portion:
420 parts of Testa Tritici, Semen Maydis flour 120 parts, bran coat 54 parts, white sugar 6 parts, Radix Puerariae 400 parts, 500 parts of water.
The present invention also provides for a kind of bioconversion mycelium, and preparation method is: by hedgehog hydnum mushroom inoculation to described culture medium
In, at 20～27 DEG C, Hericium erinaceus (Bull. Ex Fr.) Pers. is cultivated 30～40 days, dries, obtains bioconversion mycelium.
The Hericium erinaceus (Bull. Ex Fr.) Pers. of the present invention is hedgehog hydnum Cordycepps fungus Hericium erinaceus (Bull. Ex Fr.) Pers. (Hericium erinaceum (Bull.ex Fr.) Pers.).
Described bioconversion mycelium is hedgehog hydnum Cordycepps fungus Hericium erinaceus (Bull. Ex Fr.) Pers. (Hericium erinaceum (Bull.ex Fr.) Pers.)
Mycelium grow nonparasitically upon another plant with it drying composite of the solid medium containing Radix Puerariae composition.
The present invention also provides for a kind of extract, and preparation method is:
(1) bioconversion mycelium being carried out water to carry, be soaked in water at 50-70 DEG C, the weight of water is biological transformed bacteria filament weight
6～10 times of amount, obtain extracting solution；
(2) by said extracted liquid concentrating under reduced pressure, concentrated solution evacuation under the conditions of 50-70 DEG C of concentrating under reduced pressure gained is dried,
Obtain extract.
Preferably, the temperature that water soaking or evacuation are dried is 60 DEG C.
The present invention also provides for a kind of extract purposes in preparing hepatoprotective medicine or Dealcoholic sobering-up health food.
The Radix Puerariae of the present invention, another name: Radix puerariae, Radix Puerariae, Pachyrhizua angulatus, Ge Gegen, Pueraria montana (Lour.) Merr. are eaten, Ge Zigen, Radix puerariae root, the neat root of chicken,
Tuber for leguminous plant Pueraria lobota.
The invention has the beneficial effects as follows, water at low temperature of the present invention soaks bioconversion mycelium, and water soaking at 50-70 DEG C, without temperature
Degree destroys, and can dissolve effective ingredient but not destroy effective ingredient；50-70 DEG C of concentrating under reduced pressure, will not destroy effective ingredient, special
It it not active enzyme material；In order to not affect relevant active substance, under the conditions of present invention preferably employs 60 DEG C, evacuation is dried.
The mode that the present invention uses Hericium erinaceus (Bull. Ex Fr.) Pers. to ferment obtains bioconversion mycelium, then extracts it, obtains extract,
All there is under zoopery and normal individual trial good detoxifying effect.
Detailed description of the invention
Embodiment 1
A kind of bioconversion mycelium extract, its preparation method comprises the steps:
(1) agricultural byproducts Testa Tritici 490g, Semen Maydis flour 140g, bran coat 63g, white sugar 7g, and Chinese crude drug Radix Puerariae coarse powder (Pueraria lobota are taken
Root) 300g, mixing, add about 500g water and mix thoroughly, obtain culture medium.Bottle again, sterilizing, access Hericium erinaceus (Bull. Ex Fr.) Pers., at 27 DEG C
Under the conditions of convert cultivate 40 days, take out mycelium, dry, obtain bioconversion mycelium；
(2) bioconversion mycelium is taken, 60 DEG C of water soakings 2 times, to soak 2 hours every time, the weight of water be biology transformed bacteria silk
6 times of body weight；
(3) the extracting solution concentrating under reduced pressure obtained after extracting, by the concentrated solution of concentrating under reduced pressure gained evacuation under the conditions of 60 DEG C
It is dried, obtains extract.
Embodiment 2
A kind of bioconversion mycelium extract, its preparation method comprises the steps:
(1) agricultural byproducts Testa Tritici 420g, Semen Maydis flour 120g, bran coat 54g, white sugar 6g, and Chinese crude drug Radix Puerariae coarse powder (Pueraria lobota are taken
Root) 400g, mixing, add about 500g water and mix thoroughly, obtain Mycelium culture base；Bottle again, sterilizing, access Hericium erinaceus (Bull. Ex Fr.) Pers.,
Convert under the conditions of 20 DEG C and cultivate 35 days, take out mycelium, dry, obtain bioconversion mycelium；
(2) bioconversion mycelium is taken, 60 DEG C of water soakings 3 times, to soak 3 hours every time, the weight of water be biology transformed bacteria silk
8 times of body weight；
(3) the extracting solution concentrating under reduced pressure obtained after extracting, by the concentrated solution of concentrating under reduced pressure gained evacuation under the conditions of 60 DEG C
It is dried, obtains extract.
Embodiment 3
A kind of bioconversion mycelium extract, its preparation method comprises the steps:
(1) agricultural byproducts Testa Tritici 350g, Semen Maydis flour 100g, bran coat 45g, white sugar 5g, and Chinese crude drug Radix Puerariae coarse powder (Pueraria lobota are taken
Root) 500g, mixing, add about 500g water and mix thoroughly, obtain Mycelium culture base；Bottle again, sterilizing, access Hericium erinaceus (Bull. Ex Fr.) Pers.,
Convert under the conditions of 25 DEG C and cultivate 30 days, take out mycelium, dry, obtain bioconversion mycelium；
(2) bioconversion mycelium is taken, 60 DEG C of water soakings 3 times, to soak 4 hours every time, the weight of water be biology transformed bacteria silk
10 times of body weight；
(3) the extracting solution concentrating under reduced pressure obtained after extracting, by the concentrated solution of concentrating under reduced pressure gained evacuation under the conditions of 60 DEG C
It is dried, obtains extract.
Embodiment 4
Radix Puerariae mixed ratio contrast test
Hericium erinaceus (Bull. Ex Fr.) Pers. filament bioconversion industrialization is cultivated the most ripe, and raw material feeds intake in terms of siccative, and ratio is fixed as: Testa Tritici
70%, Semen Maydis powder 20%, bran coat 9%, white sugar 1%, the present invention joins Chinese crude drug Radix Puerariae as one of culture medium, Chinese crude drug Radix Puerariae
The ratio entered accounts for 30%, 40%, 50% respectively, and contrived experiment scheme, always feed intake 5000g, the ratio participated in by Radix Puerariae respectively
30%, 40%, 50% preparation culture medium, the mixing that adds water, sterilizing, inoculates, cultivates, parallel control, and condition of culture is completely the same,
Incubation is observed mycelial growth situation, growth cycle, pollution condition, the speed of growth, digs a bottle post-drying and weigh, dig bottle
Rear mycelium drying sample is respectively labeled as HG-1, HG-2, HG-3, and cellulase, Quantitative Determination of Ergosterol in detection sample (are examined
Examine conversion the most thorough), puerarin content.Result of the test is added up such as following table:
| Packet numbering | HG-1 | HG-2 | HG-3 |
| Material gross weight (g) before cultivating | 5000g | 5000g | 5000g |
| Contamination ratio (%) in incubation | 9.5% | 8.0% | 15.2% |
| Growth cycle (my god) | 33 days | 34 days | 39 days |
| The speed of growth (mm/ days) | 4.85mm/ my god | 4.71mm/ my god | 4.10mm/ my god |
| Cellulase content (U/g) | 168U/g | 174U/g | 144U/g |
| Quantitative Determination of Ergosterol (mg/g) | 0.60mg/g | 0.65mg/g | 0.48mg/g |
| Puerarin content | 1.20% | 1.80% | 1.75% |
Result of the test represents: when Radix Puerariae accounts for 50%, pollution rate is high, the speed of growth is slow, growth cycle length, cellulase ergosterol
Content is low, and bioconversion is the most thorough；And Radix Puerariae the speed of growth is very fast, growth cycle is short when accounting for 30%, but puerarin content is low；
It is the most suitable that Radix Puerariae accounts for during 40% ratio, and mycelial growth situation is preferable, takes into account each advantage, for best ratio.
Embodiment 5
Chemical liver injury animal experiment
1 material and method
1.1 samples: Hericium erinaceus (Bull. Ex Fr.) Pers. filament bioconversion industrialization is cultivated the most ripe, and raw material feeds intake in terms of siccative, and ratio is fixed
For Testa Tritici 70%, Semen Maydis powder 20%, bran coat 9%, white sugar 1%, the present invention using Chinese crude drug Radix Puerariae as one of culture medium, Chinese medicine
The ratio that material Radix Puerariae participates in accounts for 30%, 40%, 50% respectively, and contrived experiment scheme, always feed intake 5000g, participates in by Radix Puerariae respectively
Ratio 30%, 40%, 50% prepare culture medium, cultivate, extract after obtain extract, be respectively labeled as TH-1, TH-2, TH-3.
Taking Hericium erinaceus (Bull. Ex Fr.) Pers. filament, Radix Puerariae, 60 DEG C of water soakings of difference 3 times, soak 3 hours every time, the weight of water is Hericium erinaceus (Bull. Ex Fr.) Pers. filament
Or 8 times of Radix Puerariae weight；The extracting solution concentrating under reduced pressure obtained after extracting, by the concentrated solution of concentrating under reduced pressure gained 60 DEG C of conditions
Lower evacuation is dried, and obtains extract.Extract sample is respectively labeled as HTJ, GG.
Before this test, each sample is faced the used time and is configured to desired concn with distillation water as solvent.
1.2 dehydrated alcohol: analytical pure, are produced by Chongqing Chuan Dong chemical industry (group) company limited, lot number: 20140416.
1.3 experimental animals: the male SD rat 70 provided by Sichuan institute of antibiotics Experimental Animal Center, body weight is
180-220g, the quality certification number is: river reality kinoplaszm 2014-004 cleaning grade.Experimental animal room is SPF level, and the use quality certification number is
The real dynamic pipe 0143 in river, temperature is 20-25 DEG C, relative humidity 40-70%.
1.4 experiment packet and dose design: SD rat being randomly divided into seven groups, often group 10, totally 5, sample, experiment sets
The unified dosage (being respectively equivalent to 5 times of human body recommended amounts) of 210mg/kg, separately sets distilled water negative control group and 50% ethanol
Model control group.Causing liver injury model with ethanol (analytical pure), concentration of alcohol is 50% (with distilled water diluting), gavage amount
12ml/kg.bw (dosage of equivalent ethanol is 6000mg/kg.bw).
1.5 experimental techniques: use alcoholic liver injury model, select male SD rat 70, point 5 sample sets and one
Negative control group, a model control group.5 sample sets gavages equal every day give tested material, negative control group and model comparison
Group gives distilled water, by 10ml/kg.bw per os gavage once a day, gives continuously 30 days, claims weekly twice body weight, with this
Adjust dosage.50% dehydrated alcohol 12ml/kg.bw is given by model control group and gavage of 5 sample sets at the end of experiment,
Negative control group gives distilled water, puts to death animal and takes liver, weigh and calculate dirty body ratio, carrying out biochemistry with liver after fasting 16h
Indexs measure and histopathological examination.
2 Testing index
In 2.1 liver homogenate, lipid peroxide catabolite malonaldehyde (MDA) and liver homogenate reduced glutathion (GSH) all use
Being built up, by Nanjing, the kit measurement that Bioengineering Research Institute provides, the triglyceride (TG) in liver homogenate is by mikey section of Sichuan Province
The kit measurement that skill Co., Ltd provides, the mensuration of above index all uses biological Mei Liai semi-automated biological analyzer to enter
Row is analyzed.
2.2 livers are weighed and dirty system number.
2.3 pathology of hepar diagnostic criterias
2.3.1 pathological observation material: do in the middle part of animal leftlobe of liver cross section draw materials, frozen section, oil red specific stain,
Microscopic observation fat drops in the distribution in liver, scope and area.
2.3.2 pathological observation method: every example animal liver tissue 40 times of whole tissue slices of object lens Continuous Observation, each visual field root
According to positive cell, the how many and scope of distribution, marks by 0,1,2,3,4 points.Using the meansigma methods of obatained score as this
The fat stains scoring of example hepatic tissue.
2.3.3 pathological diagnosis standard: pathologic examination is using hepatocyte fat stains as observation index, and changes according to pathology
Range degree " 0 ", " 1 ", " 2 ", " 3 ", " 4 " quantify, and carry out the evaluation of hepatic injury degree.
2.3.4 hepatocyte fat stains is divided into 5 grades:
2.4 experimental data statistics: experimental data statistics uses SPSS11.0 for windows software kit to process.Matched group and
The data of sample sets are through homogeneity test of variance, and variance is neat, carries out variance analysis, if P value is less than 0.05, then use Dunnett method
Compare two-by-two；If heterogeneity of variance, then carry out data conversion, the most uneven, use rank test instead, if P value is less than 0.05,
Then compare two-by-two by Dunnett ' s T3 method.Negative control group and model control group then use T to check.
3 experimental results
3.1 extracts are on rat body weight, liver weight, the impact of liver body ratio
Table 1 extract is on rat body weight, liver weight, the impact of liver body ratio
From table 1, the original body mass of extract each sample group rat compares with negative control group, through homogeneity test of variance, side
Difference is neat (P > 0.05), and the results of analysis of variance (P > 0.05), and respectively group original body mass is equilibrium.Each treated animal body weight in mid-term,
Terminate body weight, liver weight and dirty body ratio to compare with model control group and there was no significant difference (P > 0.05), during whole experiment, move
Thing well-grown, continued weight increases, has no that poisoning symptom and death occurs in animal.
3.2 extracts are on liver homogenate MDA, the impact of GSH, TG content
Table 2 bioconversion " mycelium " is on liver homogenate MDA, the impact of GSH, TG content
Note:▲▲Represent and compare P < 0.01 with negative control group；* represent and compare P < 0.05 with model control group；**P<0.01
From table 2, in model control group liver homogenate, MDA, GSH/TG content compares with negative control group all significant difference
(P < 0.01), shows that this model is successful, and experimental system is reliable.The GSH of 3 samples of extract compares by rising with model group
High trend and TH-2 group have pole significance to raise (P < 0.01), and MDA, TG of 3 samples of extract compare with model control group
Downward trend and low, TH-2 group is all had to have significance to reduce (P < 0.05, P < 0.01).HTJ and GG group is all improved GSH also
Reduce the effect of MDA and TG, but there is no significant difference with model control group contrast.
3.3 pathology of hepars check result
The results are shown in Table 3, table 4, model control group fat stains scoring, higher than negative control group (P < 0.01), shows that this model is
Successfully, experimental system is reliable.5 sample sets hepatocyte fat scorings of tested material are compared with model group has significance to reduce
(P < 0.01, P < 0.05).
Table 3 extract is to rat liver Pathologic Observation record
Table 4 extract is to rat liver tissue pathological examination result
Note:▲▲Represent and compare P < 0.01 with negative control group；* represent and compare P < 0.05 with model control group；**P<0.01
4 brief summaries
After continuous 30 days per os gavages of extract give animal, body weight, liver weight and the liver body ratio of animal is had no significant effect, TH-2
In group liver homogenate, GSH has significance to raise, and MDA, TG of TH-1, TH-2, TH-3 group has downward trend and low, TH-2 group group
Having significance to reduce (P < 0.05, P < 0.01), histopathological examination result is positive.Thus can determine that, extract is to animal
Alcoholic liver injury has assistant protection function.
Embodiment 6 human experiment Expected Results
The extract that embodiment 2 obtains is fabricated to dry extract, and fill becomes capsule, packaging, and sample is supplied to crowd's test-meal, makees
For test-meal group.It is fabricated to health food according to alcohol-dissolving liver-protecting healthy food a kind of disclosed in China Patent Publication No. CN 1736261A,
The crowd that is supplied to tries out, group as a comparison, and test-meal situation is summarized as follows:
1) test-meal group: male 134 example, women 16 example；Test-meal personnel's age is between 18～68 years old.Contrast groups: male
132 examples, women 18 example；Test-meal personnel's age is between 18～68 years old.
2) eating method: take 4～6 in before wine 10～30 minutes.
3) evaluation methodology: to test-meal group and contrast groups personnel's release information feedback, click metrics evaluation product effective, effective,
Invalid；Effective: this product can increase capacity for liquor, relieving alcoholic intoxication is fast, it is possible to alleviates the ethanol stimulation to stomach, alleviates the most each
Plant discomfort；Effective: this product has certain sobering-up functions, alleviate the ethanol stimulation to stomach；Invalid: to take this product
Have no difference with not taking.
4) test-meal result is as follows:
| Total number of cases | Effective | Obvious effective rate (%) | Effectively | Effective percentage (%) | Total effective rate (%) | Invalid | Inefficiency (%) | |
| Test-meal group | 150 | 103 | 68.67 | 39 | 26.0 | 94.7 | 8 | 5.3 |
| Contrast groups | 150 | 84 | 56.0 | 31 | 20.67 | 76.7 | 35 | 23.3 |
Being found out by test-meal and comparing result, this product obvious effective rate reaches 68.67%, and total effective rate reaches 94.7%, is significantly higher than contrast
Product, this product can actually Dealcoholic sobering-up, alcoholic liver injury is had auxiliary protection function.
Claims (6)
1. a culture medium, is characterized in that, including the component of following weight portion:
Testa Tritici 490～350 parts, Semen Maydis flour 140～100 parts, bran coat 63～45 parts, white sugar 7～5 parts, Radix Puerariae 300～500
Part, water 400～600 parts.
2. culture medium as claimed in claim 1, is characterized in that, described culture medium includes the component of following weight portion:
420 parts of Testa Tritici, Semen Maydis flour 120 parts, bran coat 54 parts, white sugar 6 parts, Radix Puerariae 400 parts, 500 parts of water.
3. a bioconversion mycelium, is characterized in that, preparation method is: by hedgehog hydnum mushroom inoculation to such as claim 1
Or in the culture medium described in 2, at 20～27 DEG C, Hericium erinaceus (Bull. Ex Fr.) Pers. is cultivated 30～40 days, dries, obtains bioconversion mycelia
Body.
4. an extract, is characterized in that, preparation method is:
(1) bioconversion mycelium as claimed in claim 3 is carried out water to carry, be soaked in water at 50-70 DEG C, the weight of water
For 6～10 times of biological transformed bacteria filament weight, obtain extracting solution；
(2) by said extracted liquid concentrating under reduced pressure, concentrated solution evacuation under the conditions of 50-70 DEG C of concentrating under reduced pressure gained is dried,
Obtain extract.
5. extract as claimed in claim 4, is characterized in that, the temperature that water soaking or evacuation are dried is 60 DEG C.
6. the extract as described in claim 4 or 5 prepares hepatoprotective medicine or Dealcoholic sobering-up health food being used for.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610261325.4A CN105950477A (en) | 2016-04-26 | 2016-04-26 | Medium, biotransformation mycelium, extract product and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610261325.4A CN105950477A (en) | 2016-04-26 | 2016-04-26 | Medium, biotransformation mycelium, extract product and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105950477A true CN105950477A (en) | 2016-09-21 |
Family
ID=56915259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610261325.4A Pending CN105950477A (en) | 2016-04-26 | 2016-04-26 | Medium, biotransformation mycelium, extract product and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105950477A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107699501A (en) * | 2017-11-24 | 2018-02-16 | 湖南新汇制药股份有限公司 | A kind of culture medium of Hericium erinaceus, bioconversion mycelium, the mycelial extract of bioconversion and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102599481A (en) * | 2012-03-12 | 2012-07-25 | 杨毅 | Method for preparing solid fermentation mixed edible medicinal fungus sporocarp |
| CN104611232A (en) * | 2014-12-16 | 2015-05-13 | 湖南新汇制药股份有限公司 | Bioconversion mycelium and application of bioconversion mycelium extract in preparation of anticoagulant drugs |
| CN105147899A (en) * | 2015-10-09 | 2015-12-16 | 上海百信生物科技有限公司 | Preparation for protecting stomach, protecting liver and dissipating effects of alcohol and application of preparation |
-
2016
- 2016-04-26 CN CN201610261325.4A patent/CN105950477A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102599481A (en) * | 2012-03-12 | 2012-07-25 | 杨毅 | Method for preparing solid fermentation mixed edible medicinal fungus sporocarp |
| CN104611232A (en) * | 2014-12-16 | 2015-05-13 | 湖南新汇制药股份有限公司 | Bioconversion mycelium and application of bioconversion mycelium extract in preparation of anticoagulant drugs |
| CN105147899A (en) * | 2015-10-09 | 2015-12-16 | 上海百信生物科技有限公司 | Preparation for protecting stomach, protecting liver and dissipating effects of alcohol and application of preparation |
Non-Patent Citations (1)
| Title |
|---|
| 李伯骥等: "《简明化学实验室实用手册》", 30 November 1989 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107699501A (en) * | 2017-11-24 | 2018-02-16 | 湖南新汇制药股份有限公司 | A kind of culture medium of Hericium erinaceus, bioconversion mycelium, the mycelial extract of bioconversion and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101624570B (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| CN101172125B (en) | Ganoderma lucidum liquid fermentate, composition containing the fermentate , preparation method and application of the same | |
| CN104757670B (en) | A kind of licorice health care plant beverage and preparation method thereof | |
| CN112438354A (en) | Plant fermentation liquor and preparation method and application thereof | |
| CN104904962A (en) | Complex fermented gynostemma pentaphylla type Chinese herbal medicine health tea | |
| CN106418525A (en) | Fermenting folium mori chewable tablet and preparation method thereof | |
| CN102021101B (en) | Preparation method of healthy wine for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN104212730A (en) | Honey fermented wine | |
| CN109498744A (en) | A kind of preparation method that composite bacteria fermentation compound eucommia bark leaf is scattered | |
| CN103932180B (en) | A kind ofly to release the pressure and the health food of antifatigue and two-step fermentation preparation method thereof | |
| CN106924548A (en) | The medicine and preparation method of a kind of fatigue-relieving | |
| KR20040052655A (en) | Fermented Vinegar and Method of Preparing the Same | |
| CN105950477A (en) | Medium, biotransformation mycelium, extract product and application | |
| CN106070783A (en) | A kind of production technology of Semen Coicis damp eliminating tea | |
| CN105602787A (en) | Bee pupa/Cordyceps militaris health-care wine, and preparation method and application thereof | |
| CN113274478B (en) | Traditional Chinese medicine fermentation preparation for treating gout and preparation method thereof | |
| CN108850571A (en) | A kind of crisp shape of the mouth as one speaks cattle feed and preparation method thereof | |
| CN108157939A (en) | A kind of food with hypoglycemic effect and preparation method thereof | |
| CN107670002A (en) | A kind of hypoglycemic composition and its preparation method and application | |
| CN104886252A (en) | Compound traditional Chinese medicine antialcoholic yogurt and preparation technology thereof | |
| CN105838538A (en) | Formula and preparation method of dark tea golden camellia health care wine | |
| CN106819682B (en) | A kind of Chinese chive juice of warm kidney and preparation method thereof | |
| CN107699501A (en) | A kind of culture medium of Hericium erinaceus, bioconversion mycelium, the mycelial extract of bioconversion and application thereof | |
| CN110547397A (en) | Nutritional meal replacement food for tumor rehabilitation and preparation method thereof | |
| CN110754662B (en) | Yellow blood silkworm cordyceps militaris chicken essence electuary suitable for people prone to fatigue and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |